TABLE 1

Physical and metabolic characteristics of the study populations in the cross-sectional, prospective, and longitudinal analyses

Baseline population
Prospective analysis
Longitudinal analysis
Means ± SDRange (min–max)Non-progressorsProgressorsBaselineFollow-up
n45130763224224
Age (years)30 ± 618–4726 ± 627 ± 626 ± 630 ± 6
Body weight (kg)98 ± 2650–25791 ± 2399 ± 22*92 ± 2398 ± 26
Body fat (%)33 ± 89–5330 ± 935 ± 731 ± 931 ± 11
WTR1.68 ± 0.181.06–2.581.61 ± 0.161.65 ± 0.181.61 ± 0.151.67 ± 0.16
Fasting plasma glucose (mmol/l)4.9 ± 0.62.8–7.14.8 ± 0.55.2 ± 0.54.9 ± 0.54.9 ± 0.6
2-h plasma glucose (mmol/l)7.1 ± 1.83.1–10.95.9 ± 1.16.6 ± 0.85.9 ± 1.16.6 ± 1.6
Fasting plasma insulin (pmol/l)254 ± 11567–677210 ± 102250 ± 102210 ± 96234 ± 114
M-low (mg · kg EMBS−1 · min−1)2.57 ± 0.881.41–6.543.00 ± 1.272.39 ± 0.752.98 ± 1.332.72 ± 0.98
M-high (mg · kg EMBS−1 · min−1)8.6 ± 2.12.4–13.79.4 ± 2.058.6 ± 1.99.4 ± 2.08.9 ± 2.2
AIR (pmol/l)1,416 ± 93343–7,1641,569 ± 1,0421,307 ± 751*1,638 ± 1,0261,542 ± 1,104
Basal endogenous glucose output (mg · kg EMBS−1 · min−1)1.95 ± 0.241.32–2.591.90 ± 0.241.91 ± 0.271.90 ± 0.241.97 ± 0.24
HGO (mg · kg EMBS−1 · min−1)0.42 ± 0.390–1.930.29 ± 0.340.40 ± 0.36*0.32 ± 0.360.43 ± 0.40
ALT (units/l)45 ± 295–14436 ± 2539 ± 2935 ± 2641 ± 30
AST (units/l)34 ± 1811–10332 ± 1533 ± 1532 ± 1632 ± 19
GGT (units/l)56 ± 398–24549 ± 3554.1 ± 3844 ± 2750 ± 31
ALKP (units/l)111 ± 4250–27995 ± 42101 ± 5990 ± 45109.1 ± 43
Bilirubin (μmol/l)11 ± 52–3412 ± 911 ± 47 ± 66 ± 3
Fasting plasma albumin (g/l)40 ± 428–5141 ± 439 ± 441 ± 440 ± 4
  • Symbols indicate significant differences between progressors and nonprogressors in the prospective analysis (unpaired t test) and between baseline and follow-up variables (except for age) in the longitudinal analysis (paired t test).

  • *

    * P = 0.05;

  • P < 0.001;

  • P < 0.01. ALKP, alkaline phosphatase; EMBS, estimated metabolic body size = fat free mass + 17.7 kg.